Is pregnant, breastfeeding, or is planning to become pregnant during the study period

Has received aripiprazole lauroxil or IM depot aripiprazole within 6 months, or other long-acting, injectable antipsychotic medication within 3 months

Is a danger to himself/herself at screening or upon admission

Has a history of or positive test result for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C

Has a positive urine drug screen at screening or Day 1

Additional criteria may apply

An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

What this study is about